Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Thrilled to be part of the GRObio mission! Congratulations to the team! https://t.co/Xe6gSujYHV
Dan and his team are pushing ahead with their revolutionary vision. Non-standard amino acids allowing for novel proteins, useful across multiple diseases and situations. Pillar has been glad to back GRObio from the pre-Seed til now, with a wonderful and expanding syndicate. https://t.co/pqF5LhRBF9
I am thrilled to announce @gro_bio's $60.3M Series B financing, co-led by @atlasventure and Access Biotechnology! This financing is the culmination of an enormous body of work by our entire company, including our GRO platform, product pipeline, and business development personnel,…
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.